Investors
About Picard Medical, Inc.
Picard Medical, Inc. (NYSE: PMI) is the parent company of SynCardia Systems, LLC, a global innovator in total artificial heart technology. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (STAH), the only commercially available total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada. SynCardia is a wholly owned subsidiary of Picard Medical. Picard Medical became a publicly traded company on August 29, 2025.
About SynCardia Systems, LLC
Founded in 2001 by Dr. Jack Copeland, Richard Smith, and Dr. Marvin Slepian, SynCardia carries forward the legacy of CardioWest and the pioneering Jarvik-7 design. With more than 2,100 implants performed across 27 countries, the STAH has over three decades of proven clinical use.
Available in 70 cc and 50 cc sizes, the STAH is supported by hospital-based and portable home driver systems that allow patients to regain mobility and quality of life while awaiting a donor heart. Looking forward, SynCardia is developing the fully implantable Emperor System, designed to eliminate external drivers and set a new standard in total artificial heart therapy.
You have landed on the Investor Relations site for Picard Medical, Inc. For more information about SynCardia’s products, patients, and technology, please visit www.syncardia.com.
